

# MARKET REPORT



## Ulcerative Colitis [2016]: Bulletin #3

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



## Ulcerative Colitis [2016]: Bulletin #3

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Ulcerative Colitis [2016]: Bulletin #3

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the European Commission approval of Amgevita (biosimilar adalimumab) in all available indications, including moderate-to-severe UC.

Business Questions:

How do KOLs regard real-world analyses of Entyvio?

What potential threats could Entyvio face in the future?

What are KOL views on Kappaproct and how would this agent be used if approved?

What impact is Amgevita/Amjevita expected to have on the UC anti-TNF market?

According to KOLs, which anti-TNF biosimilar is expected to have the most success in UC?

## Additional Details

**Publisher :** FirstWord Pharma

**Reference :**

**Number of Pages :** 0

**Report Format :** PDF

**Publisher Information :**

**FirstWord**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for Ulcerative Colitis [2016]: Bulletin #3

# How to Buy...

Ulcerative Colitis [2016]: Bulletin #3

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/107184>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

**\$888** | Single User Price

**\$2189** | Global License Price

**Payment Options:** (please tick one)

**Online Credit Card** (we will email you the invoice with a payment link)

**Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.